Race Oncology Limited (ASX: RAC) has announced a major scientific breakthrough that could reshape its commercial and clinical trajectory. The company has discovered that bisantrene – a clinically validated cancer drug – exists as three photoisomers, with only the (E,E)-bisantrene form possessing significant anticancer activity. This discovery has enabled Race to file three new patent applications, potentially providing composition of matter intellectual property (IP) protecti